TNFSF10 and neoplasm: Despite this ability to selectively induce apoptosis in a variety of tumor and transformed cells without affecting normal cells, TRAIL was perceived to have notable shortcomings as a short-lived protein therapeutic that limited interest in its clinical development [1, 3].